These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32861983)

  • 1. Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.
    Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Park L; Zarate CA
    J Psychiatr Res; 2020 Nov; 130():280-285. PubMed ID: 32861983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
    Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
    J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.
    Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Zarate CA; Park LT
    J Affect Disord; 2020 Feb; 263():568-575. PubMed ID: 31791675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
    Niciu MJ; Shovestul BJ; Jaso BA; Farmer C; Luckenbaugh DA; Brutsche NE; Park LT; Ballard ED; Zarate CA
    J Affect Disord; 2018 May; 232():310-315. PubMed ID: 29501990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
    Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
    Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of ketamine on typical and atypical depressive symptoms.
    Park LT; Luckenbaugh DA; Pennybaker SJ; Hopkins MA; Henter ID; Lener MS; Kadriu B; Ballard ED; Zarate CA
    Acta Psychiatr Scand; 2020 Nov; 142(5):394-401. PubMed ID: 32677051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression.
    Aepfelbacher J; Panny B; Price RB
    Biol Psychiatry Glob Open Sci; 2024 Jul; 4(4):100316. PubMed ID: 38726038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
    J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disentangling the association of depression on the anti-fatigue effects of ketamine.
    Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
    J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.